Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 929 shares of Natera stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $93.14, for a total value of $86,527.06. Following the completion of the transaction, the insider now directly owns 110,748 shares of the company's stock, valued at $10,315,068.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Natera Stock Up 1.4 %
NASDAQ:NTRA opened at $94.15 on Thursday. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The stock has a 50-day simple moving average of $89.57 and a 200-day simple moving average of $68.74.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million during the quarter, compared to analysts' expectations of $300.38 million. On average, equities analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.
Wall Street Analyst Weigh In
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
NTRA has been the subject of a number of research reports. The Goldman Sachs Group lifted their price objective on shares of Natera from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, April 15th. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday. Craig Hallum assumed coverage on Natera in a research report on Monday, April 8th. They set a "buy" rating and a $117.00 price objective on the stock. Raymond James lowered Natera from a "strong-buy" rating to an "outperform" rating and lifted their target price for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Stephens reissued an "overweight" rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $86.40.
Get Our Latest Report on NTRA
Institutional Investors Weigh In On Natera
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Natera during the fourth quarter worth about $83,970,000. American Century Companies Inc. grew its stake in Natera by 115.7% during the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company's stock worth $73,203,000 after buying an additional 887,409 shares during the last quarter. Invesco Ltd. increased its position in Natera by 52.0% during the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock worth $111,930,000 after buying an additional 865,404 shares during the period. Perceptive Advisors LLC increased its position in Natera by 289.7% during the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company's stock worth $53,258,000 after buying an additional 632,047 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company's stock valued at $687,280,000 after buying an additional 588,147 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Company Profile
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
